Last updated: March 26, 2026
What is the case about?
Amgen Inc. filed a patent infringement lawsuit against Aurobindo Pharma Limited in the District of Delaware. The case involves Amgen's biologic drug patents and Aurobindo's production of a biosimilar claimed to infringe those patents.
Case timeline and procedural posture
- Filing Date: January 10, 2022
- Docket Number: 1:22-cv-00037
- Parties: Amgen Inc. (plaintiff), Aurobindo Pharma Limited (defendant)
- Legal claims: Patent infringement under the Hatch-Waxman Act
- Relief sought: Injunctive relief, damages, declaration of patent validity
Patent claims involved
Amgen's patents relate to biotechnology processes and specific formulations for erythropoietin (EPO), a biologic used for anemia treatment. Key patents include:
- US Patent No. 9,900,826
- US Patent No. 10,204,326
These patents cover purified EPO compositions and methods of manufacturing.
Allegations of infringement
Amgen contends that Aurobindo’s biosimilar product, which seeks FDA approval, infringes on Amgen's patent rights by manufacturing a biologic highly similar to Amgen's biologics.
- The complaint alleges that Aurobindo's biosimilar violates the '826 and '326 patents.
- Aurobindo's product allegedly infringes via the manufacturing process and composition claims.
Aurobindo's defenses
Aurobindo has filed motions to dismiss and argues:
- The patents are invalid due to obviousness and lack of novelty.
- The claims are indefinite under patent law.
- The biosimilar does not infringe because it differs in manufacturing process specifics.
Court proceedings and filings
- Preliminary filings: Amgen filed for preliminary injunction shortly after complaint.
- Responses: Aurobindo challenged the patent validity through motions to dismiss.
- Discovery: Ongoing as of the most recent filings in early 2023.
- Trial date: Not yet scheduled; case remains in early stages.
Legal issues
Patent validity
Key challenge relates to whether the patents are valid under 35 U.S.C. § 102 (novelty) and § 103 (non-obviousness). Aurobindo’s legal team asserts prior art references that could anticipate or render the patents obvious.
Infringement
The core issue centers on whether Aurobindo’s biosimilar product infringes the claims of Amgen’s patents, with focus on composition and process claims.
Market implications
- The case concerns the biosimilar market for EPO, estimated at a global CAGR of 21% (IQVIA, 2022).
- An unfavorable ruling for Aurobindo could delay biosimilar entry, prolonging exclusivity for Amgen.
- A ruling favoring Aurobindo might accelerate biosimilar market entry, impacting Amgen’s revenue.
Stakeholder positions
- Amgen: Seeks to enforce patent rights and delay biosimilar competition.
- Aurobindo: Aims to clear patent barriers, seeking FDA approval and market entry.
Recent developments
- Aurobindo’s motion to dismiss remains pending.
- Court has not issued a preliminary ruling on patent validity.
- Parties are engaged in discovery, with a trial possible in 2024.
Analysis
Strengths for Amgen
- Broad patent claims possibly covering the manufacturing process.
- Previous enforcement success in biosimilar patent disputes.
Challenges for Amgen
- Potential patent invalidity arguments may succeed, especially on obviousness grounds.
- Litigation costs and delays could weaken enforceability.
Strengths for Aurobindo
- Validity defenses may succeed if prior art anticipates or makes obvious the patented inventions.
- The recent trend in biosimilar cases favors validity challenges.
Risks and opportunities
- Acurate court interpretation could lead to early invalidation, reducing patent longevity.
- Success may halt biosimilar entry or limit manufacturing claims.
Key takeaways
- The case hinges largely on patent validity and infringement proofs.
- A preliminary decision is unlikely before late 2023.
- The outcome will influence biosimilar markets, especially for erythropoietin products.
- Both parties plan extensive discovery, possibly extending litigation into 2024.
- The case exemplifies ongoing patent challenges in the biologics space.
FAQs
1. What is the primary legal issue in Amgen v. Aurobindo?
Patent infringement and validity of Amgen’s biologic patents related to erythropoietin.
2. When will a court decision likely occur?
No ruling is expected before late 2023; case scheduling remains ongoing.
3. What impact could this case have on the biosimilar market?
An adverse ruling for Aurobindo could delay biosimilar entry, extending Amgen’s market exclusivity.
4. Are there any prior similar cases?
Yes, Amgen has previously enforced patents against biosimilar competitors, such as in 2017 against Hospira.
5. What are the key legal arguments Aurobindo is using?
Lack of patent novelty and obviousness, and non-infringement based on manufacturing variations.
References:
- IQVIA. (2022). The Biosimilars Market Report.
- U.S. Patent and Trademark Office. (2022). Patent Files for Nos. 9,900,826 and 10,204,326.
- Court filings from Amgen Inc. v. Aurobindo Pharma Limited, D. Del., 1:22-cv-00037, 2022–2023.
